Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised $276 million in an upsized IPO this month (see "Gossamer Bio Prices $276M IPO").

Cancer company Verastem Inc. (NASDAQ:VSTM) hired Amy Cavers as SVP of strategic engagement and alignment and Robert Morgan as SVP of development operations. Cavers was VP of scientific affairs at TG Therapeutics Inc. (NASDAQ:TGTX) and Morgan was chief regulatory/quality and contracting officer of Samus Therapeutics Inc. (Topsfield, Mass.)...